Clinical Trial Update: Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluated adding Nateglinide to Pioglitazone in patients with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Nateglinide (nateglinide)
• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Type 2 Diabetes Mellitus, Diabetes Mellitus, Type II | Phase 2, Phase 3 | Status: COMPLETED